对埃索梅普拉的药理动力学和CYP2C19基因多态性的关联研究
Yuan Fang1,2, Xia He1,2,3,4, Ai Peng1,2,3,4
1Department of Gastroenterology, West China Hospital, Sichuan University, Wuhou, Chengdu, P.R. China.
Clinical pharmacology in drug development
|September 29, 2023
概括
CYP2C19基因变异显著影响身体如何处理埃索梅普拉 (一种质子抑制剂). 这项研究在中国参与者中发现了埃索梅普拉的药理动力学与这些遗传差异之间的明显联系.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 临床药理学 临床药理学
背景情况:
- 埃索梅普拉是一种广泛使用的质子抑制剂.
- 已知CYP2C19基因多态性会影响药物代谢.
- 了解这些变异对于个性化医学至关重要.
研究的目的:
- 检查埃索梅普拉的药理动力学与CYP2C19基因多态性之间的关系.
- 评估不同的CYP2C19代谢器状态如何影响埃索梅普拉的药物水平.
- 评估与基因型有关的埃索梅普拉的安全性和耐受性.
主要方法:
- 研究了一组95名健康的中国参与者.
- 参与者接受口服剂量为20毫克或40毫克的埃索梅普拉.
- 用PCR-RFLP进行了CYP2C19的基因型鉴定;用HPLC-UV测量了血度.
主要成果:
- 在CYP2C19代谢组 (差,中等,快速) 中观察到埃索梅普拉的终端消除半衰期和暴露 (AUC/剂量,Cmax/剂量) 的显著差异.
- 到最大度的时间没有显著的变化.
- 对于20毫克或40毫克剂量都没有报告任何意外不良事件.
结论:
- 埃索梅普拉的新陈代谢受到CYP2C19基因多态化的显著影响.
- 这些发现支持药物遗传学在优化埃索梅普拉治疗中的作用.
- 埃索梅普拉在本研究队列中显示出良好的安全性和耐受性.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
186
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
186
Factors Affecting Protein-Drug Binding: Patient-Related Factors
73
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
73
Factors Influencing Drug Absorption: Disease States and Pharmacology
551
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
551
Time Course of Drug Effect
2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Analysis of Population Pharmacokinetic Data
282
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
282
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K


